- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04335942
Characterization of the Postural Habits of Wheelchair Users Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor (Es-Alert)
Characterization of the Postural Habits of Wheelchair Users in an Ecological Situation and Analysis of the Acceptability of International Recommendations in the Prevention of Pressure Sores Risk by Using a Connected Textile Sensor Integrating an Artificial Intelligence Algorithm
Spinal cord injuries and people with Duchenne Muscular Dystrophy or Infant Spinal Muscular Atrophy (ISA) are prone to pain and pressure sores associated with prolonged sitting. For this reason, it is recommended that people with spinal cord injuries release pressure every 15 to 30 minutes and motorized wheelchair users use the electric positioning functions at least 1 minute every hour.
The aim is to prevent and/or reduce pain and pressure sores. These devices could help to observe daily the variability of users' pressure maps, their impact on occupational performance, the link with pain and redness and could propose customized adjustments.
Study Overview
Status
Intervention / Treatment
Detailed Description
The main objective of this study is to evaluate the impact of an algorithm that characterizes the cruro-ischiatic fingerprints used in daily life and that issues an alert in case of detection of a pressure sore risk defined by the literature on the occupational performance of the subjects.
The resulting assumption is based on the following points:
- The algorithms implemented in this device are able to calculate and isolate a number of cruro-ischiatic fingerprints used during the day during priority activities and active or passive position changes.
- They may, in the event of a risk position, issue alerts based on the recommendations.
This will allow us to analyze the impact of these alerts on the changes in position and relief actually performed by the subject, analyze the consequences on the MCRO score (psychosocial impact on occupational performance) and verify the impact of visual biofeedback on chair positioning.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Caroline Hugeron, MD
- Phone Number: +33 01 47 10 70 62
- Email: caroline.hugeron@aphp.fr
Study Contact Backup
- Name: Antoine Perrier, PhD
- Phone Number: +33 06.83.54.13.08
- Email: perrier.antoine@gmail.com
Study Locations
-
-
-
Garches, France, 92380
- Hôpital Raymond Poincaré
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men or women over 18 years of age,
Daily user of a FR (more than 3 hours per day):
- Persons with Duchenne Muscular Dystrophy (DMD) or DMB using an FRE,
- People with Infant Spinal Muscular Atrophy (ISA) using an FRE,
- WB persons using an MRA with sensitivity disorders (ASIA A).
FRE allowing a switchover of at least:
- 25° of the seat and 120° of the backrest,
- 45° of sitting in one block,
- Patient who has signed an informed and written consent,
- Affiliation to a social security scheme (beneficiary or beneficiary).
Exclusion Criteria:
- Refusal of the patient to participate in the study,
- School level lower than cycle 3 not allowing to understand the use of the embedded device,
- Severe incontinence,
- BM without sensitivity disorders,
- Participant in another study or therapeutic trial,
- Patient under guardianship or curatorship,
- Pregnant women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: AFNOR 3.6 alerts
Alert called "AFNOR 3.6" in connection with the dispersion index described by Drummond et al 1985 and validated by Sprigle et al 2003.
This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),
|
This alert corresponds to the quantification of the percentage of weight on the slick distributed over a small area (55% on one to three zones totalling 30cm2),
|
Other: AFNOR 3.6 alerts and Guidelines
AFNOR 3.6" alerts and "Guidelines" alerts.
By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes (Bergstrom et al., 1992; Nixon, 1985; Ho and Bogie, 2007) over a period of 1 minute 51 (Coggrave and Rose 2003) for spinal cord injuries.
For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block (Dicianno et al. 2009).
|
By alertes Guidelines we mean the clinical recommendations of the Spinal Cord medicine association, i.e. weight relief every 15 to 30 minutes over a period of 1 minute 51 for spinal cord injuries.
For patients who do not push up, a tilt of at least 25° of seat and 120° of backrest or a minimum of 45° in one block.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluate the impact of a device, monitoring the wheelchair user's risk of pressure sores and issuing alerts based on international recommendations, on the support reliefs provided by the subject in an ecological situation
Time Frame: 14 days
|
Primary outcome will be evaluated with the number of modification of relief or changing of position with or without alert.
The metric used will be the number of average reliefs per hour performed by the patient.
This number of reliefs will be compared with and without an alert system.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the differences in occupational performance at the MCRO (Mesure canadienne du rendement occupationnel) score
Time Frame: 14 days
|
Analyze the differences in occupational performance at the MCRO score.
An improvement in MCRO score will mean an improvement of occupational performance in psychosocial dimensions.
|
14 days
|
the impact of visual biofeedback of the pressure print on chair
Time Frame: 14 days
|
Quantify the impact of visual biofeedback of the pressure print on chair positioning by modification of the seat within 5 minutes following the visual cartography consultation
|
14 days
|
Feasibility study of integrating international recommendations to reduce the risk of pressure ulcers in a medical device
Time Frame: 14 days
|
the aim is to verify the technical feasibility of integrating international recommendations to reduce the risk of pressure ulcers in a medical device in relation to the position in the chair through: adequacy between pressure cartography the same label posture over time as well as adequacy between the alert and the type of pressure imprint
|
14 days
|
the study of the acceptability by the patient of alerts in relation with international recommendations
Time Frame: 14 days
|
the study of the acceptability by the patient of alerts in relation with international recommendations will be evaluated with the duration of change in alert characteristics by patient after two days of non-modifiable alerts
|
14 days
|
the study of the acceptability by the patient of alerts in relation with international recommendations
Time Frame: 14 days
|
the study of the acceptability by the patient of alerts in relation with international recommendations will be evaluated with the frequency of change in alert characteristics by patient after two days of non-modifiable alerts
|
14 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Caroline Hugeron, MD, Hôpital Raymond Poincaré
Publications and helpful links
General Publications
- Drummond D, Breed AL, Narechania R. Relationship of spine deformity and pelvic obliquity on sitting pressure distributions and decubitus ulceration. J Pediatr Orthop. 1985 Jul-Aug;5(4):396-402. doi: 10.1097/01241398-198507000-00002.
- Gawlitta D, Li W, Oomens CW, Baaijens FP, Bader DL, Bouten CV. The relative contributions of compression and hypoxia to development of muscle tissue damage: an in vitro study. Ann Biomed Eng. 2007 Feb;35(2):273-84. doi: 10.1007/s10439-006-9222-5. Epub 2006 Nov 29.
- Sprigle S, Maurer C, Holowka M. Development of valid and reliable measures of postural stability. J Spinal Cord Med. 2007;30(1):40-9. doi: 10.1080/10790268.2007.11753913.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Skin Diseases
- Neurologic Manifestations
- Skin Ulcer
- Genetic Diseases, Inborn
- Genetic Diseases, X-Linked
- Musculoskeletal Diseases
- Muscular Diseases
- Neuromuscular Diseases
- Neurodegenerative Diseases
- Neuromuscular Manifestations
- Pathological Conditions, Anatomical
- Spinal Cord Diseases
- Muscular Disorders, Atrophic
- Atrophy
- Motor Neuron Disease
- Muscular Dystrophies
- Muscular Atrophy
- Muscular Dystrophy, Duchenne
- Muscular Atrophy, Spinal
- Pressure Ulcer
Other Study ID Numbers
- APHP190924
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
-
ItalfarmacoCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
Santhera PharmaceuticalsTerminatedDuchenne Muscular Dystrophy (DMD)United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Hospital RudolfstiftungOesterreichische MuskelforschungCompletedCarrier of Duchenne Muscular DystrophyAustria
-
General Hospital of Chinese Armed Police ForcesUnknownDuchenne Muscular Dystrophy (DMD)China
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
University of FloridaU.S. Army Medical Research and Development CommandRecruitingDuchenne Muscular Dystrophy (DMD)United States
-
PTC TherapeuticsCompletedNonsene Mutation Duchenne Muscular DystrophyUnited States
Clinical Trials on Alert "AFNOR 3.6".
-
Brigham and Women's HospitalSanofiCompletedDeep Vein Thrombosis | Venous Thromboembolism | Pulmonary Embolism | Prevention | ProphylaxisUnited States
-
Columbia UniversityEnrolling by invitationSepsis | Electronic Health Records | Clinical Decision Support SystemsUnited States
-
University of California, San FranciscoCompleted
-
Yale UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Columbia UniversityEnrolling by invitationSepsis | Electronic Health Records | Clinical Decision Support SystemsUnited States
-
Peptigroupe Inc.CompletedDysfunctional Uterine BleedingUkraine
-
Imperial College LondonCompletedType1diabetesUnited Kingdom
-
Luye Pharma Group Ltd.CompletedProstate CancerChina
-
Guangdong Provincial People's HospitalUnknownAcute Kidney Injury
-
Dana-Farber Cancer InstituteCompletedBreast Cancer | Gastrointestinal Cancer | Oral Cancer Directed Therapy | Oral ChemotherapyUnited States